Welcome to our dedicated page for Treace Medical Concepts SEC filings (Ticker: TMCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Treace Medical Concepts, Inc. (TMCI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed medical technology company focused on bunion and related midfoot deformities, Treace uses these filings to report financial results, material agreements, governance changes and risk factors relevant to TMCI stockholders.
Investors can review annual reports on Form 10‑K for a detailed discussion of Treace’s business, including its Lapiplasty 3D Bunion Correction System, Adductoplasty Midfoot Correction System, minimally invasive Nanoplasty and Percuplasty systems, SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants, IntelliGuide patient specific technology, and associated risk factors and market considerations. Quarterly reports on Form 10‑Q provide interim financial statements, management’s discussion and analysis and updates on operations and liquidity.
Current reports on Form 8‑K capture specific material events, such as the entry into new senior secured term loan and revolving credit agreements, repayment and termination of prior credit facilities, earnings releases for quarterly periods and changes in the composition or roles of the board of directors. These filings outline key terms of financing arrangements, including collateral, interest rates, covenants and potential implications for dividend payments.
Users can also monitor proxy statements and related materials for information on governance, board structure and executive compensation, as well as Section 16 filings such as Form 4 for reports of insider transactions in TMCI shares. Stock Titan’s platform pairs these documents with AI‑powered summaries that explain complex sections, highlight notable items and help readers quickly understand how new filings may relate to Treace’s bunion‑focused business, financial condition and capital structure.
With real‑time updates from EDGAR and structured access to key forms, this page serves as a central resource for analyzing TMCI’s regulatory history and ongoing disclosure record.
Treace Medical Concepts provides an overview of its business focused on surgical solutions for bunions and related midfoot deformities. The company highlights its flagship Lapiplasty 3D Bunion Correction System and complementary platforms such as Adductoplasty, Nanoplasty, Percuplasty, SpeedMTP, SpeedPlate, IntelliGuide, and a hammertoe system.
The filing describes a U.S.-focused commercial model with a 297-person field sales fleet and extensive surgeon training and direct-to-patient marketing, including National Bunion Day. It outlines large addressable markets for bunion surgery, summarizes favorable interim clinical data from ALIGN3D and Mini3D studies, details an active R&D pipeline including Lapiplasty Lightning, and notes 450 employees, robust patent and trademark portfolios, and a capital‑light manufacturing strategy using third‑party suppliers.
Treace Medical Concepts reported 2025 revenue of
Cash, cash equivalents and marketable securities were
For 2026, Treace guided to revenue of
TREACE MEDICAL CONCEPTS, INC. reported that Armistice Capital, LLC and Steven Boyd jointly hold 6,364,000 shares, representing 9.99% of the outstanding common stock.
The filing states the reported shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital exercises shared voting and dispositive power under an Investment Management Agreement. The joint filing is signed by Steven Boyd on 02/17/2026.
Treace Medical Concepts, Inc. is the subject of an amended Schedule 13G filing showing significant institutional and insider ownership of its common stock. Neil Gagnon reports beneficial ownership of 6,142,107 shares, or 9.6% of the class, based on 63,718,073 shares outstanding as of October 31, 2025.
Gagnon Securities LLC reports beneficial ownership of 3,928,051 shares (6.2%), and Gagnon Advisors, LLC reports 1,534,034 shares (2.4%). Neil Gagnon has sole voting and dispositive power over 420,406 shares and shared voting and/or dispositive power over additional shares held in managed accounts and a private fund, while expressly disclaiming beneficial ownership of securities held for clients.
The filing certifies that the securities were not acquired and are not held to change or influence control of Treace Medical Concepts, but rather on a passive, investment basis consistent with Schedule 13G requirements.
Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, exercised stock options and received common shares. On February 10, 2026, a stock option for 16,875 shares with a $1.05 exercise price was exercised, converting into 16,875 shares of common stock. Following this transaction, Scanlan directly beneficially owned 706,474 shares of common stock, which includes 511,291 restricted stock units.
William Blair Investment Management, LLC filed an amended Schedule 13G reporting its beneficial ownership of 1,145,498 shares of Treace Medical Concepts, Inc. common stock, representing 1.8% of the class as of the triggering date.
The firm has sole voting power over 879,228 shares and sole dispositive power over all 1,145,498 shares, with no shared voting or dispositive power. It certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Treace Medical Concepts.
Treace Medical Concepts, Inc. reported an equity award to its Chief Commercial Officer, Gaetano Guglielmino. On January 22, 2026, he was granted 150,000 restricted stock units (RSUs) of common stock at a price of $0 per share. Each RSU converts into one share of common stock as it vests. The RSUs vest in four equal annual installments, starting on January 22, 2027 and ending on January 22, 2030, conditioned on his continued service with the company. Following this grant, he beneficially owns 490,901 shares of common stock, including 422,250 RSUs.
Treace Medical Concepts Chief Legal & Compliance Officer Scot Michael Elder reported equity compensation and related share movements. On January 22, 2026, he disposed of 9,451 shares of Common Stock in a transaction coded "F" at a price of $0 per share, leaving him with 534,286 shares beneficially owned immediately after that line item. The same day, he acquired 262,500 shares of Common Stock in a transaction coded "A" at $0 per share, reported as restricted stock units.
The footnotes explain that these 262,500 RSUs each convert into one share of Common Stock upon vesting and vest in equal annual installments over four years, from January 22, 2027 through January 22, 2030, subject to continued service. After the reported transactions, Elder is shown as beneficially owning 796,786 shares, which includes 641,470 restricted stock units.
Treace Medical Concepts' Chief Financial Officer Mark Hair reported equity compensation activity in company stock. On January 22, 2026, he disposed of 17,037 shares of Common Stock at a stated price of $0, leaving him with 493,208 shares directly owned after that transaction, which included 351,134 restricted stock units.
On the same date, he was awarded 375,000 restricted stock units (RSUs) for which he is entitled to receive one share of Common Stock per RSU upon vesting at no cost. These RSUs vest in equal annual installments over four years, from January 22, 2027 through January 22, 2030, subject to his continued service. Following this grant, he directly beneficially owned 868,208 shares, which included 726,134 restricted stock units.
Treace Medical Concepts Chief Innovation Officer Sean F. Scanlan reported equity transactions in company stock. On January 21, 2026, he exercised a stock option for 53,500 shares of Common Stock at an exercise price of $0.72 per share, converting a previously held option into directly owned shares. On January 22, 2026, he received a grant of 262,500 restricted stock units (RSUs), each RSU representing one future share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years from January 22, 2027 through January 22, 2030, contingent on his continued service with the company.